このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Boai NKY Medical Holdings マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Junzheng Zhang

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	4.8yrs
CEOの所有権	0.2%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Junzheng Zhang (48 yo)

4.8yrs

在職期間

CN¥312,000

報酬

Mr. Junzheng Zhang serves as Chairman of the Board and Chief Executive Offier at Boai NKY Medical Holdings Ltd. He served as Secretary of the Board at Boai NKY Medical Holdings Ltd. (formerly known as Boai...

取締役

名称	ポジション	在職期間	報酬	所有権
Junzheng Zhang	Chairman of the Board & GM	4.8yrs	CN¥312.00k	0.20% CN¥ 10.2m
Donghu Wang	Director	no data	CN¥336.90k	9.09% CN¥ 474.0m
Hongbo Yang	Vice Chairman of the Board	4.8yrs	CN¥315.40k	0.22% CN¥ 11.2m
Wei Zhao	Non-Independent Director	4.8yrs	CN¥120.00k	0.0072% CN¥ 374.7k
Tong Zhou	Independent Director	4.8yrs	CN¥108.00k	データなし
Yunxia Qu	Chairman of the Supervisory Board	4.8yrs	CN¥173.70k	データなし
Chunping Li	Non-Employee Supervisor	4.8yrs	データなし	データなし
Dalong Ren	Vice Chairman of the Board	8.6yrs	CN¥259.30k	データなし
Haifeng Liu	Supervisor	4.8yrs	データなし	データなし
Rui Zhao	Independent Director	2.4yrs	データなし	データなし
Yongjun Fang	Independent Director	2.4yrs	CN¥90.00k	データなし
Tao Chang	Non-Employee Supervisor	1.3yrs	データなし	0.0032% CN¥ 168.9k

4.8yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: 300109の取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Boai NKY Medical Holdings マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Boai NKY Medical Holdings Ltd., Annual General Meeting, May 23, 2024

High number of new directors

High number of new and inexperienced directors

Recent updates

Boai NKY Medical Holdings Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dividend increased to CN¥1.00

Boai NKY Medical Holdings Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 07 June 2024

Boai NKY Medical Holdings Ltd. Approves Cash Dividend for the Year 2023

Boai NKY Medical Holdings Ltd., Annual General Meeting, May 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.39 in 1Q 2023)

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2023

Now 23% overvalued after recent price rise

Boai NKY Medical Holdings Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥1.63 (vs CN¥0.88 in FY 2022)

Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding

Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding

Investor sentiment deteriorates as stock falls 20%

Boai NKY Medical Holdings Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.42 in 3Q 2022)

Boai NKY Medical Holdings Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.34 in 2Q 2022)

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 30, 2023

Boai NKY Medical Holdings Ltd. Approves Cash Dividend for 2022

First quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.10 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.91 in FY 2021)

Investor sentiment deteriorated over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.046 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Gryningskust Holding AB acquired additional 14.0 % minority stake in NeoDynamics AB (publ) (OM:NEOD).

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 30 May 2022

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 30 May 2022

Boai Nky Medical Holdings Ltd. Approves Cash Dividend

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.19 in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Boai NKY Medical Holdings Ltd. (SZSE:300109) commences a Equity Buyback Plan under the authorization approved on December 21, 2021.

Third quarter 2021 earnings released: EPS CN¥0.046 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.067 (vs CN¥0.12 in 2Q 2020)

Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Shanghai Haitong Securities Assets Management Co.,Ltd. completed the acquisition of 3% stake in Boai NKY Medical Holdings Ltd. (SZSE:300109) from Wang Donghu.

Boai Nky Medical Holdings Ltd. Approves Final Cash Dividend for 2020

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.04 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥11.20

New 90-day low: CN¥11.89

Ningbo Tianlong Electronics Co., Ltd. (SHSE:603266) entered into a equity transfer agreement to acquire 4.1818% stake in Wuhan First Bioscience Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for CNY 14 million.

New 90-day low: CN¥13.80

New 90-day low: CN¥15.06

New 90-day low: CN¥16.55

Third quarter earnings released

Market bids up stock over the past week

New 90-day high: CN¥19.40

New 90-day high: CN¥19.24

Fang Huasheng and Ren Dalong acquired 18.99% stake in Boai NKY Pharmaceuticals Ltd. (SZSE:300109).

New 90-day high - CN¥18.63

Earnings released

Boai NKY Medical Holdings Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥18.55

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14